ArticleOncology reports2017
The ethanol extracts of sporoderm-broken spores of Ganoderma lucidum inhibit colorectal cancer in vitro and in vivo.
Article in Oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Natural Remedies for Gut Health: The Role of Plant Extracts in Combating Inflammatory Bowel Disease and Colon Cancer.Food science & nutrition · 2026Review
- Article
- CanPharmaceuticals (Basel, Switzerland) · 2025Review
- Pan-genomic characterization and structural variant analysis reveal insights into spore development and species diversity inMicrobial genomics · 2024Article
- Bibliometric, taxonomic, and medicinal perspectives ofMycology · 2024Review
- Pharmacological Activities and Safety of Ganoderma lucidum Spores: A Systematic Review.Cureus · 2023Review
- A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer.Chinese medicine · 2023Review
- Mycochemicals against Cancer Stem Cells.Toxins · 2023Review
- Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model.Molecules (Basel, Switzerland) · 2023Article
- Are chemical compounds in medical mushrooms potent against colorectal cancer carcinogenesis and antimicrobial growth?Cancer cell international · 2022Review
- Article
- Comparative transcriptome analysis of genes and metabolic pathways involved in sporulation in Ganoderma lingzhi.G3 (Bethesda, Md.) · 2022Article
- Sporoderm-Broken Spores ofFrontiers in pharmacology · 2022Article
- Extract ofPharmaceutical biology · 2021Article
- Astragalin Inhibits the Proliferation and Migration of Human Colon Cancer HCT116 Cells by Regulating the NF-κB Signaling Pathway.Frontiers in pharmacology · 2021Article
- Article
- Meroterpenoids With Protein Tyrosine Phosphatase 1B Inhibitory Activities From the Fruiting Bodies ofFrontiers in chemistry · 2020Article
- Water Extract of Sporoderm-Broken Spores ofOncoTargets and therapy · 2019Article
- Effects of non-steroidal anti-inflammatory drug-activated gene-1 on Ganoderma lucidum polysaccharides-induced apoptosis of human prostate cancer PC-3 cells.International journal of oncology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The medicinal mushroom Ganoderma lucidum (G. lucidum) has been reported to possess a variety of pharmacological activities including anticancer effects. However, the anti-colorectal cancer effects and the potential molecular mechanisms of the ethanol extracts of sporoderm-broken spores of G. lucidum (BSGLEE), which mainly contains triterpenoids, have not been reported. The aim of the present study was to investigate the anticancer effects and molecular mechanisms exerted by BSGLEE on colorectal cancer in vitro and in vivo. MTT assay revealed that BSGLEE at 1.6 to 10 mg/ml significantly inhibited HCT116 cell proliferation in a dose- and time-dependent manner. Flow cytometric analysis demonstrated that BSGLEE induces apoptosis and cell cycle arrest at G0/G1 phase, which are associated with deregulation of the expression of key genes and proteins (p21, p16, cyclin D1, Bcl-2, bax, NAG-1, PARP and caspase-3) that regulate apoptosis and cell cycle cascades. Moreover, BSGLEE significantly inhibited HCT116 cell migration via downregulating MMP-1, MMP-2 and upregulating E-cadherin expression at mRNA levels. Oral gavage of 75 and 150 mg/kg BSGLEE significantly inhibited HCT116 xenograft tumor growth in nude mice, which was accompanied by suppressed Ki-67 staining as determined by immunochemistry. Collectively, we found that BSGLEE effectively inhibits colorectal cancer carcinogenesis through induction of apoptosis, inhibition of migration and promotion of cell cycle arrest. Our results suggest that triterpenoids of sporoderm-broken spores of G. lucidum ethanol extracts may serve as a promising anticancer agent for colorectal cancer chemoprevention and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.